

1 **Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-**  
2 **wide meta-analysis and Mendelian randomisation**

3

4 Sizheng Steven Zhao<sup>1</sup>, Sarah L Mackie<sup>2,3</sup>, Susanna C Larsson<sup>4,5</sup>, Stephen Burgess<sup>6,7,8</sup>, Shuai Yuan<sup>4</sup>

5

6 1 Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science,  
7 School of Biological Sciences, Faculty of Biological Medicine and Health, The University of  
8 Manchester, Manchester Academic Health Science Centre, Manchester, UK

9 2 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

10 3 National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals,  
11 University of Leeds, Leeds, UK

12 4 Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine,  
13 Karolinska Institutet, Nobelsväg 13, 17177, Stockholm, Sweden

14 5 Department of Surgical Sciences, Uppsala University, Dag Hammarskjölds Väg 14B, 75185, Uppsala,  
15 Sweden

16 6 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and  
17 Primary Care, University of Cambridge, Cambridge, UK

18 7 Heart and Lung Research Institute, University of Cambridge, Cambridge UK

19 8 Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK

20

21 **Correspondence to:** Dr Sizheng S Zhao. Centre for Musculoskeletal Research, Division of  
22 Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological  
23 Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre,  
24 Oxford Road, Manchester, M13 9LJ, UK. Email: [Sizheng.zhao@manchester.ac.uk](mailto:Sizheng.zhao@manchester.ac.uk)

25

26 **Abstract**

27 **Objective:** Polymyalgia rheumatica (PMR) is an age-related inflammatory disease of unknown cause.  
28 We aimed to identify potentially modifiable risk factors and therapeutic targets for preventing or  
29 treating PMR.

30 **Methods:** We meta-analysed genetic association data from 8,156 cases of PMR (defined using  
31 diagnostic codes and self-report) and 416,495 controls of European ancestry from the UK Biobank  
32 and FinnGen. We then performed Mendelian randomization analyses to estimate the association  
33 between eight modifiable risk factors (using data from up to 1.2 million individuals) and 65  
34 inflammation-related circulating proteins (up to 55,792 individuals), using the inverse variance  
35 weighted and pleiotropy robust methods.

36 **Results:** We identified three novel genome-wide significant loci in the *IL1R1*, *NEK6* and *CCDC88B*  
37 genes and confirmation of previously described associations with *HLA-DRB1* and *ANKRD55*.  
38 Genetically predicted smoking intensity (OR 1.32; 95%CI 1.08-1.60;  $p=0.006$ ) and visceral adiposity  
39 (OR 1.22; 95%CI 1.10-1.37;  $p=3.10 \times 10^{-4}$ ) were associated with PMR susceptibility. Multiple circulating  
40 proteins related to IL-1 family signaling were associated with PMR. IL-1 receptor-like 2, also known as  
41 IL-36 receptor (OR 1.25;  $p=1.89 \times 10^{-32}$ ), serum amyloid A2 (OR 1.06,  $9.91 \times 10^{-10}$ ) and CXCL6 (OR 1.09,  
42  $p=4.85 \times 10^{-7}$ ) retained significance after correction for multiple testing.

43 **Conclusion:** Reducing smoking and visceral adiposity at a population level might reduce incidence of  
44 PMR. We identified proteins that may play causal roles in PMR, potentially suggesting new  
45 therapeutic opportunities. Further research is needed before these findings are applied to clinical  
46 practice.

47 **Keywords:** genome-wide meta-analysis, interleukin-1, smoking, obesity, adiposity, polymyalgia  
48 rheumatica

49 **Key messages:**

- 50 1) Three novel PMR risk loci were identified in *IL1R1*, *NEK6* and *CCDC88B*.  
51 2) Several circulating proteins, notably those involved in IL-1 family signalling, are associated with  
52 PMR susceptibility.  
53 3) Visceral adiposity and cigarette smoking are causally associated with risk of PMR.

54

55

## 56 **Introduction**

57 Polymyalgia rheumatica (PMR) is an age-related inflammatory disease of unknown cause (1). The  
58 pattern of inflammation of PMR centres on certain tendon, ligaments, and joint capsules, but  
59 without radiographic change in adjacent articular bone (2). There is overlap with giant cell arteritis  
60 (GCA) and both diseases have been postulated to preferentially initiated at mechanically-stressed  
61 sites (3,4). The intense systemic inflammatory response of PMR hampers efforts to disentangle true  
62 causal factors from epiphenomena related to systemic inflammation or compensatory/counter-  
63 regulatory mechanisms. To date, poor understanding of PMR aetiopathogenesis has been a barrier to  
64 progress in its definition, diagnosis, and treatment. Currently, long-term oral glucocorticoids are the  
65 primary treatment used, at the cost of substantial treatment toxicity (1).

66 Like GCA, PMR is more commonly diagnosed in northern European countries, but genetic and  
67 environmental contribution to this geographical distribution is unclear. Genome-wide association  
68 studies have yielded mechanistic insights into GCA implicating angiogenesis and neutrophils (5).  
69 Historically, genetic association data in PMR has been contradictory or inconclusive due to  
70 underpowering and historic use of candidate gene methods (1). Recently, we reported that  
71 genetically proxied IL-6 receptor (6) and IL-1 receptor antagonism (7) are both associated with  
72 reduced risk of PMR. In the current genetic investigation, we aimed to identify potentially modifiable  
73 risk factors and inflammation-related circulating proteins as targets of intervention for preventing or  
74 treating PMR.

## 75 **Methods**

### 76 Study design

77 We performed a genome wide association study (GWAS) meta-analysis using data from the UK  
78 Biobank and FinnGen. Genetic association data was used in Mendelian randomization (MR) analyses  
79 of selected modifiable risk factors and inflammation-related circulating proteins. Ethical approval was  
80 obtained by the FinnGen and UK Biobank (application 72723) studies to which participants provided  
81 written informed consent.

### 82 GWAS of UK Biobank and FinnGen

83 The UK Biobank is a cohort study of approximately 500,000 individuals aged 40-69 years, recruited  
84 between 2006 and 2010 (8). It includes self-reported data on diseases, linked hospital admissions  
85 data, the national death register, and primary care data for a subset of ~225,000 participants. Quality  
86 control of UK Biobank genotype data has been described previously (8). The current analysis was  
87 restricted to unrelated (kinship $\geq$ 0.084) individuals of self-reported White-British ancestry, with

88 concordant submitted and genetically inferred sex. GWAS was performed using SNPTEST v2.5.4,  
89 adjusting for the first four principal components derived using cases and controls. Variants with  
90 minor allele frequency of <0.01 and INFO score of <0.5 were excluded. PMR was defined using any of  
91 the following: ICD 10 code M353 (from fields 41270, 40001 or 40002), self-report (code 1377 in field  
92 20002), or Read code N20.. or XE1FJ in linked primary care data. GWAS comprised 4,285 cases of  
93 PMR (3180 ICD, 1073 self-report, 1239 Read) and 17,140 randomly selected controls without PMR  
94 (1:4 ratio to reduce case-control imbalance that can increase type I error (9,10)) and was adjusted for  
95 the first four principal components.

96 FinnGen is a large research study comprising genetic and health data from 500,000 Finnish  
97 participants. Quality control steps have been previously described. We used Release 10 (December  
98 2023) summary-level data on PMR, comprising 3,871 cases and 399,355 controls. PMR was defined  
99 by ICD code 10th (M353), 9th (725), or 8th (4463) revisions. Genetic associations were adjusted for  
100 age, sex, principal components, and genotyping batch.

101 We combined summary statistics from UK Biobank and FinnGen under a fixed effects model using  
102 the METAL software (11) and examined the heterogeneity in SNP-PMR associations across the two  
103 studies. LD Score regression was used to evaluate the heritability, genomic inflation factor ( $\lambda$ ),  
104 and intercept (12).

#### 105 Mendelian randomization analysis

106 MR analyses used genetic association data from the above GWAS meta-analysis comprising a total of  
107 8,156 PMR cases and 416,495 controls. We first investigated the association between eight  
108 modifiable environmental or lifestyle risk factors and PMR, including three obesity indicators (body  
109 mass index (BMI) (13), waist circumference (14), and visceral adiposity (15)) and five lifestyle factors  
110 (smoking initiation (16), smoking intensity measured in cigarettes per day (16), alcohol (16) and  
111 coffee consumption (17), and moderate-to-vigorous physical activity (18)). To identify potential  
112 therapeutic targets, we conducted MR analyses of 66 inflammation-related circulating proteins (19–  
113 21) in relation to PMR susceptibility. **Table S1** provides information on GWASs from which genetic  
114 association data for these exposures were derived.

115 For the eight modifiable risk factors, we selected SNPs associated with the exposures of interest at  
116 the genome-wide significance threshold ( $P < 5 \times 10^{-8}$ ) from their respective GWASs. For the  
117 inflammation-related circulating proteins, only *cis*-acting SNPs (i.e., within  $\pm 250$  kb of the gene  
118 encoding the relevant protein) were selected. For all exposures, we excluded SNPs exhibiting high  
119 linkage disequilibrium (LD) ( $r^2 > 0.01$ , using the 1000 Genomes European reference panel), retaining

120 only the SNP with the lowest  $P$  value from the GWAS association. For inflammation-related  
121 circulating proteins with a limited number of SNPs as genetic instruments, we sought proxy SNPs that  
122 had a high LD ( $r^2 > 0.8$ ) with those SNPs that were not available.

123 For exposures with two SNPs as instruments, we used the inverse variance weighted method under a  
124 fixed effects model to estimate their association with risk of PMR; otherwise, we used the  
125 multiplicative random effects inverse variance weighted method. For exposures proxied by multiple  
126 SNPs, we conducted sensitivity analyses, including the weighted median and MR-Egger methods, to  
127 validate the robustness of our findings and detect and address potential horizontal pleiotropy. We  
128 used Cochran's  $Q$  value to assess the heterogeneity among the SNP estimates. Multiple testing  
129 corrections were implemented using the Benjamini-Hochberg false discovery rate (FDR) method. All  
130 analyses were based on two-sided tests and performed using the TwoSampleMR and  
131 MendelianRandomization packages in R (version 4.1.1).

## 132 **Results**

### 133 Genome-wide association analysis

134 This GWAS meta-analysis included 424,651 individuals (8,156 cases and 416,495 non-cases).  
135 Assuming a lifetime prevalence of 2% among those of European ancestry (22), the heritability of PMR  
136 on a liability scale explained by common genetic variants (minor allele frequency (MAF)  $\geq 0.05$ ) was  
137 estimated at  $h^2_{liab} = 0.09$  (95% CI 0.06-0.11). The genomic inflation factor,  $\lambda_{GC}$ , was calculated to be  
138 1.06, suggesting a minimal inflation due to population stratification or other confounding factors.  
139 The LD score regression intercept was estimated at 0.99 (standard error=0.008), indicating a good  
140 alignment with the null expectation of no polygenicity.

141 We annotated five genome-wide significant loci (**Figure 1**), with *IL1R1* (rs11694915), *NEK6*  
142 (rs748741), *CCDC88B* (rs615540) being previously unreported (**Table 1**), and *HLA-DRB1* and *ANKRD55*  
143 consistent with prior reports (23). rs2760985 (tagging *HLA-DRB1*) was the most pronounced  
144 association observed. It was also the only SNP with statistical evidence of heterogeneity across  
145 FinnGen and UK Biobank cohorts, but estimates were directionally concordant (**Table S2**).

### 146 Mendelian randomization analysis

147 Of the eight modifiable risk factors, genetically predicted levels of BMI, visceral adiposity and  
148 smoking intensity (cigarettes per day) were associated with PMR (**Figure 2**). Genetically predicted  
149 smoking intensity was associated with 1.32-fold higher odds of PMR per standard deviation (SD)  
150 increase (95%CI 1.08-1.60;  $p=0.006$ ). Higher genetically predicted BMI (OR 1.16 per SD increase;  
151 95%CI 1.03-1.31;  $p=0.013$ ) and visceral adiposity (OR 1.22 per SD increase; 95%CI 1.10-1.37;

152  $p=3.10 \times 10^{-4}$ ) were also associated with PMR risk. After false discovery rate (FDR) multiple-testing  
153 correction, associations with visceral adiposity and smoking intensity retained significance. There  
154 was no statistical evidence of directional pleiotropy (**Table S3**). Genetically predicted levels of the  
155 other modifiable risk factors showed no significant associations with PMR susceptibility.

156 Of the inflammation-related circulating proteins, suitable genetic instruments were identified for 65.  
157 Genetically predicted levels of 12 inflammatory markers were associated with susceptibility to PMR  
158 (**Figure 3**) including various proteins in the IL-1 family signaling pathways. After adjusting for multiple  
159 testing, only the associations for IL-1 receptor-like 2 (also known as IL-36 receptor) (OR 1.25; 95%CI  
160 1.21, 1.30;  $p=1.89 \times 10^{-32}$ ), serum amyloid A2 protein (OR 1.06; 95%CI 1.04, 1.07;  $p=9.91 \times 10^{-10}$ ) and  
161 CXCL6 (CXC motif chemokine 6) (OR 1.09; 95%CI 1.05, 1.13;  $p=4.85 \times 10^{-7}$ ) remained significant. Full  
162 results for all inflammation-related circulating proteins are shown in **Table S4**. The three SNPs used  
163 to instrument IL-1 receptor-like 2 are in close proximity to the *IL1R1* SNP identified in GWAS and may  
164 represent the same underlying association; rs3917265 is correlated with rs11694915 (*IL1R1*) with  $r^2$   
165 of 0.11).

## 166 Discussion

167 This, the largest GWAS meta-analysis of PMR to date, has identified three novel loci in the *IL1R1*,  
168 *NEK6* and *CCDC88B* genes and confirmation of previously described associations with *HLA-DRB1* and  
169 *ANKRD55*. Moreover, we found causal associations between PMR and levels of circulating proteins  
170 involved in IL-1 family signalling (potentially explained by the same IL-1 GWAS signal), the acute  
171 phase response (serum amyloid A2), and neutrophil chemotaxis, angiogenesis and tendon repair  
172 (CXCL6). MR analyses identified visceral adiposity and cigarette smoking as modifiable risk factors for  
173 PMR.

174 The next largest published genetic association study of PMR, to our knowledge, was an exome-wide  
175 analysis of 559 cases and 15,620 controls (24). That prior study identified two SNPs in the HLA  
176 region, rs3096702 (which the authors could not replicate) upstream of *Notch4* and rs6910071 in  
177 *C6orf10*. A conference abstract that similarly combined UK Biobank and an earlier release of FinnGen  
178 data identified SNPs close to the *HLA-DRB1* gene and the same intronic variant in *ANKRD55* as in the  
179 current study (23). *ANKRD55* variants have been linked to expression of the neighbouring *IL6ST* gene  
180 in various immune cells (25). *IL6ST* encodes part of a cytokine receptor complex that act as a signal  
181 transducer shared by multiple cytokines, including IL-6. These findings are supported by a prior  
182 Mendelian randomization study linking genetically proxied IL-6R inhibition and reduced PMR risk (6),  
183 and additionally by the current results for IL-6 receptor subunit alpha. These genetic findings may be

184 viewed as supporting the relevance of IL-6 signalling in PMR, consistent with clinical trial efficacy of  
185 IL-6R inhibition (26,27).

186 Genes encoding proteins involved in IL-1 signalling have been identified in prior candidate gene  
187 studies of PMR, for example *IL1RN* (28). We previously showed that genetically proxied IL-1R  
188 antagonism is associated with PMR risk (7). Multiple IL-1 family members were implicated in the  
189 current hypothesis-free genome-wide and inflammatory-protein-wide association analyses, but most  
190 did not survive correction for multiple testing. Canakinumab, an IL-1b inhibitor, reduced PMR disease  
191 activity in a 2-week proof of concept study of five patients (29) but large-scale trials of IL-1  
192 antagonism in PMR are lacking. The only IL-1 family protein to survive multiple testing was IL-1  
193 receptor like 2, also known as the IL-36 receptor. Activation of the IL-36 receptor can induce trained  
194 immunity in monocytes (30) and has a variety of other functions (31) depending on cellular context.  
195 IL-36 receptor inhibitors have been approved for generalised pustular psoriasis (32) but not yet  
196 trialled in PMR.

197 Serum amyloid A2, one of the inducible serum amyloid A (SAA) proteins, was the only hepatic acute-  
198 phase protein that survived multiple testing in our analysis. In addition to being highly inducible in  
199 liver by IL-6 and IL-1, this lipophilic protein also acts as a damage-associated molecular pattern  
200 (DAMP) molecule and may be secreted by macrophages or adipocytes (33,34). *In vitro*, SAA can  
201 induce macrophage IL-1b secretion via activation of the NLRP3 inflammasome; in the circulation this  
202 effect is abrogated by SAA binding to high-density lipoprotein, which inactivates it (35). SAA can also  
203 recruit neutrophils and activate their glycolytic pathways *in vitro* (36). In an *ex vivo* model of GCA  
204 serum amyloid A can promote angiogenesis (37). Serum amyloid A1 and A2 have also been  
205 implicated in other Th17-associated inflammatory diseases (38). A phase III trial of secukinumab for  
206 PMR is ongoing (NCT04930094).

207 CXCL6, also known as GCP-2, is one of the pro-angiogenic chemokines, originally described as a  
208 neutrophil chemoattractant. In macrophage and endothelial cell lines, SAA synergises with CRP to  
209 upregulate CXCL6 alongside CXCL8, another neutrophil chemoattractant (39). Fibroblasts from  
210 patients with ulcerative colitis produce IL-6 upon stimulation by IL-17 (40). In a study that used  
211 single-cell techniques to characterise cell subpopulations from healthy and diseased human tendons  
212 taken from near the myotendinous junction, CXCL6 was among the inflammatory/alarmin genes that  
213 were overexpressed by microfibril-associated tenocytes in chronic tendinopathy (41). Intriguingly, in  
214 a model of tendon injury in the horse, IL-1b, released after injury, “licensed” mesenchymal stem cells  
215 (MSCs) to secrete an array of reparative and immunomodulatory factors, including CXCL6 (42). In the  
216 mouse meniscus-defect model, extracellular vesicles (EVs) secreted by human MSCs upregulated

217 local chondrocyte and MSC CXCL5 and CXCL6 expression; the EVs promoted chondrocyte growth and  
218 migration and this effect could be abrogated by blocking CXCL5 and CXCL6, or their common  
219 receptor. It was concluded that CXCL5 and CXCL6 were involved in stimulating cartilage response to  
220 injury (43). CXCL6 is a multifunctional molecule. Via its action on (human) CXCR1/2, it promotes  
221 cartilage repair (44); but also, via binding to local glycosaminoglycans, CXCL6 creates a chemokine  
222 concentration gradient that brings in neutrophils that can exacerbate tissue damage (45).

223 Challenges of interpreting observational studies illustrate the complex relationship between  
224 adiposity, PMR susceptibility and glucocorticoid toxicity. On the one hand, active (undiagnosed) PMR  
225 causes weight loss. IL-6 has a key role in thermoregulation; it is produced by muscle in response to  
226 exercise, promoting lipolysis, and is also secreted by beige adipocytes in response to cold exposure.  
227 IL-6 itself promotes further “beiging” to convert pro-inflammatory white adipose tissue towards  
228 thermogenic “beige” adipose tissue (46), promoting energy utilisation and weight loss. On the other  
229 hand, glucocorticoid treatment causes visceral adiposity, which is strongly correlated with  
230 cardiovascular risk. Aging can also lead to accumulation of visceral adipose tissue. Similarly, smoking  
231 can alter both innate and adaptive immune responses, with persistent effects especially on adaptive  
232 immunity long after individuals quit smoking (47) as well as impairing tissue perfusion, healing and  
233 angiogenesis. It remains to be seen whether smoking and adiposity, as well as being amenable to  
234 lifestyle change, might also prove useful for identifying patients with PMR who are at higher risk of  
235 adverse outcomes.

236 This study highlights previously-unappreciated aspects of the aetiopathogenesis of PMR, a disease  
237 with a characteristic pattern of inflammation of certain tendon and ligament sites (2) that are under  
238 high mechanical stress (4). In young individuals, mechanical stress from physical activity or high BMI  
239 elicits in adaptive changes such as increase in cross-sectional area and tendon stiffness; however, this  
240 ability to respond to mechanical stress is lost in older people (48). Visceral adipose tissue contains  
241 activated immune cells producing IL-1b and IL-6 with systemic effects. Fat deposition in and around  
242 muscles, entheses and tendons occurs with aging or obesity, and may contribute to chronic  
243 tendinopathy (49).

244 Antagonistic pleiotropy is a theory to explain why genes causing age-associated diseases can persist  
245 in populations despite natural selection. Hypothetically, a genetic tendency to greater IL-1 induced  
246 local CXCL6 release might hasten healing of injuries in youth, and protect joints from damage; but  
247 delayed healing in aging, or the pro-inflammatory effect of visceral adiposity, would lead to a chronic  
248 damage-repair cycle with persistent local inflammation and neoangiogenesis, that might be



249 exacerbated by the same genetic tendency. This hypothesis could be further investigated in healthy  
250 volunteers of different genotypes, ages and visceral adiposity levels.

251 The comparatively large number of PMR cases is a strength of the current study, but there are also  
252 limitations. First, our analyses focused on populations of European ancestry, potentially limiting the  
253 generalizability of our findings to other populations. Second, PMR cases were defined using clinical  
254 diagnostic codes, which may introduce misclassification. There is a lack of genetic data from large-  
255 scale inception cohorts of well-characterised PMR patients. Furthermore, there are no formal  
256 diagnostic criteria for PMR and thus no gold standard other than expert clinical opinion. In practice,  
257 the clinical diagnostic boundaries between PMR and “elderly-onset” seronegative RA are defined by  
258 clinical convention and consensus. Better mechanistic understanding of the differences between  
259 these two diseases, and between PMR and GCA, may enable dividing-lines between these diseases  
260 to be drawn more accurately in future. Multimodal approaches including genetic evidence will be  
261 needed.

262 In conclusion, this study identified three novel PMR risk loci in *IL1R1*, *NEK6* and *CCDC88B* and  
263 confirmed previously described associations with *HLA-DRB1* and *ANKRD55*. The importance of the  
264 *IL1R1* locus was supported by causal associations between circulating proteins involved in IL-1 family  
265 signalling and PMR risk. Results also suggested visceral adiposity and cigarette smoking to be  
266 potentially modifiable risk factors for PMR. These findings improve the current understanding of the  
267 genetic underpinning of PMR, and propose potential new avenues for prevention and treatment.

268

269

## 270 **Acknowledgements**

271 SSZ is supported by a National Institute for Health Research (NIHR) Academic Clinical Lectureship.  
272 SLM is supported in part by the NIHR Leeds Biomedical Research Centre (grant NIHR203331). The  
273 views expressed are those of the authors and not necessarily those of the National Health Service,  
274 the NIHR, or the Department of Health. This work was supported by Versus Arthritis (grant number  
275 21173, grant number 21754 and grant number 21755) and by the NIHR Manchester Biomedical  
276 Research Centre. SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom  
277 Research and Innovation Medical Research Council (MC\_UU\_00002/7, MC\_UU\_00040/01).

278 **Data availability statement:** UK Biobank data are available to all bona fide researchers for use in  
279 health-related research that is in the public interest. The application procedure is described at  
280 [www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk). GWAS meta-analysis data will be made publicly available upon publication.

281 **Ethics approval:** Ethical approval was obtained by the UK Biobank study. The current analysis was  
282 performed under application number 72723.

283 **Patient and Public Involvement:** Patients or the public were not involved in the design, or conduct,  
284 or reporting, or dissemination plans of this research.

285 **Conflicts of Interest:** SLM reports: Consultancy on behalf of her institution for Roche/Chugai, Sanofi,  
286 AbbVie, AstraZeneca, Pfizer; Investigator on clinical trials for Sanofi, GSK, Sparrow;  
287 speaking/lecturing on behalf of her institution for Roche/Chugai, Vifor, Pfizer, UCB, Novartis,  
288 Fresenius Kabi and AbbVie; chief investigator on STERLING-PMR trial, funded by NIHR; patron of the  
289 charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support  
290 from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend ACR Convergence 2021  
291 virtually. All other authors declare no conflicts of interest that could bias this work.

## 292 References

- 293 1. Espígol-Frigolé G, Dejaco C, Mackie SL, Salvarani C, Matteson EL, Cid MC. Polymyalgia  
294 rheumatica. *The Lancet*. 2023 Oct 21;402(10411):1459–72.
- 295 2. Owen CE, Poon AMT, Liu B, Liew DFL, Yap LP, Yang V, et al. Characterising polymyalgia rheumatica  
296 on whole-body 18F-FDG PET/CT: an atlas. *Rheumatol Adv Pract*. 2024 Feb 20;8(1):rkae003.
- 297 3. Dejaco C, Brouwer E, Mason JC, Buttgerit F, Matteson EL, Dasgupta B. Giant cell arteritis and  
298 polymyalgia rheumatica: current challenges and opportunities. *Nat Rev Rheumatol*. 2017  
299 Oct;13(10):578–92.
- 300 4. Mackie SL, Owen CE, Buchanan RRC, McGonagle D. A shared basis for overlapping  
301 immunopathologies in giant cell arteritis and polymyalgia rheumatica. *The Lancet Rheumatology*.  
302 2021 Dec 1;3(12):e826–9.
- 303 5. Borrego-Yaniz, G, Ortiz-Fernández, L, Madrid-Paredes, A et al. (49 more authors) (Accepted:  
304 2024) Angiogenesis- and NETosis-related risk loci involved in giant cell arteritis susceptibility by a  
305 genome-wide association study. *The Lancet Rheumatology*. ISSN 2665-9913 (In Press).
- 306 6. Zhao SS, Gill D. Genetically proxied IL-6 receptor inhibition and risk of polymyalgia rheumatica.  
307 *Ann Rheum Dis*. 2022 Jun 14;annrheumdis-2022-222578.
- 308 7. Zhao SS, Rajeswaran T, Mackie SL, Yarmolinsky J. Genetically proxied IL-1 receptor antagonism  
309 and risk of polymyalgia rheumatica. *Rheumatology*. 2024 Feb 1;63(2):e43–4.
- 310 8. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with  
311 deep phenotyping and genomic data. *Nature*. 2018 Oct;562(7726):203–9.
- 312 9. Zengini E, Hatzikotoulas K, Tachmazidou I, Steinberg J, Hartwig FP, Southam L, et al. Genome-  
313 wide analyses using UK Biobank data provide insights into the genetic architecture of  
314 osteoarthritis. *Nat Genet*. 2018 Apr;50(4):549–58.
- 315 10. Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, et al. Efficiently controlling  
316 for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat*  
317 *Genet*. 2018 Sep;50(9):1335–41.
- 318 11. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association  
319 scans. *Bioinformatics*. 2010 Sep 1;26(17):2190–1.
- 320 12. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the  
321 Psychiatric Genomics Consortium, et al. LD Score regression distinguishes confounding from  
322 polygenicity in genome-wide association studies. *Nat Genet*. 2015 Mar;47(3):291–5.
- 323 13. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of  
324 genome-wide association studies for body fat distribution in 694 649 individuals of European  
325 ancestry. *Human Molecular Genetics*. 2019 Jan 1;28(1):166–74.
- 326 14. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic loci  
327 link adipose and insulin biology to body fat distribution. *Nature*. 2015 Feb 12;518(7538):187–96.

- 328 15. Karlsson T, Rask-Andersen M, Pan G, Höglund J, Wadelius C, Ek WE, et al. Contribution of  
329 genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. *Nat Med*.  
330 2019 Sep;25(9):1390–5.
- 331 16. Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels gene  
332 discovery for tobacco and alcohol use. *Nature*. 2022 Dec;612(7941):720–4.
- 333 17. Zhong VW, Kuang A, Danning RD, Kraft P, van Dam RM, Chasman DI, et al. A genome-wide  
334 association study of bitter and sweet beverage consumption. *Hum Mol Genet*. 2019 Jul  
335 15;28(14):2449–57.
- 336 18. Wang Z, Emmerich A, Pillon NJ, Moore T, Hemerich D, Cornelis MC, et al. Genome-wide  
337 association analyses of physical activity and sedentary behavior provide insights into underlying  
338 mechanisms and roles in disease prevention. *Nat Genet*. 2022 Sep;54(9):1332–44.
- 339 19. Yarmolinsky J, Robinson JW, Mariosa D, Karhunen V, Huang J, Dimou N, et al. Association  
340 between circulating inflammatory markers and adult cancer risk: a Mendelian randomization  
341 analysis. *eBioMedicine* [Internet]. 2024 Feb 1 [cited 2024 Mar 1];100. Available from:  
342 [https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(24\)00026-4/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00026-4/fulltext)
- 343 20. Pietzner M, Wheeler E, Carrasco-Zanini J, Raffler J, Kerrison ND, Oerton E, et al. Genetic  
344 architecture of host proteins involved in SARS-CoV-2 infection. *Nat Commun*. 2020 Dec  
345 16;11(1):6397.
- 346 21. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the  
347 human plasma proteome. *Nature*. 2018 Jun;558(7708):73–9.
- 348 22. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The Lifetime  
349 Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic  
350 Diseases. *Arthritis Rheum*. 2011 Mar;63(3):633–9.
- 351 23. Hocaoglu M, Mikdashi J, Perry J, Hong C. Association of HLA-DRB1 and ANKRD55/IL6ST Regions  
352 with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank  
353 and FinnGen [abstract]. *Arthritis Rheumatol*. 2023; 75 (suppl 9).  
354 [https://acrabstracts.org/abstract/association-of-hla-drb1-and-ankrd55-il6st-regions-with-](https://acrabstracts.org/abstract/association-of-hla-drb1-and-ankrd55-il6st-regions-with-polymyalgia-rheumatica-diagnosis-a-genome-wide-association-study-from-uk-biobank-and-finn-gen/)  
355 [polymyalgia-rheumatica-diagnosis-a-genome-wide-association-study-from-uk-biobank-and-](https://acrabstracts.org/abstract/association-of-hla-drb1-and-ankrd55-il6st-regions-with-polymyalgia-rheumatica-diagnosis-a-genome-wide-association-study-from-uk-biobank-and-finn-gen/)  
356 [finngen/](https://acrabstracts.org/abstract/association-of-hla-drb1-and-ankrd55-il6st-regions-with-polymyalgia-rheumatica-diagnosis-a-genome-wide-association-study-from-uk-biobank-and-finn-gen/). Accessed April 14, 2024.
- 357 24. Mosley JD, Witte JS, Larkin EK, Bastarache L, Shaffer CM, Karnes JH, et al. Identifying genetically  
358 driven clinical phenotypes using linear mixed models. *Nat Commun*. 2016 Apr 25;7:11433.
- 359 25. Mena J, Alloza I, Tulloch Navarro R, Aldekoa A, Díez García J, Villanueva Etxebarria A, et al.  
360 Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene  
361 Region in Immature Dendritic Cells. *Front Immunol*. 2021;12:816930.
- 362 26. Bonelli M, Radner H, Kerschbaumer A, Mrak D, Durechova M, Stieger J, et al. Tocilizumab in  
363 patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised  
364 controlled trial. *Annals of the Rheumatic Diseases* [Internet]. 2022 Feb 24 [cited 2022 Mar 29];  
365 Available from: <https://ard.bmj.com/content/early/2022/02/23/annrheumdis-2021-221126>
- 366 27. Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, et al. Sarilumab for  
367 Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. *New England Journal of*  
368 *Medicine*. 2023 Oct 5;389(14):1263–72.

- 369 28. Alvarez-Rodriguez L, Carrasco-Marin E, Lopez-Hoyos M, Mata C, Fernandez-Prieto L, Ruiz-Soto M,  
370 et al. Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory  
371 chronic conditions: Association of IL-1RN\*2/2 genotype with polymyalgia rheumatica. *Hum*  
372 *Immunol.* 2009 Jan;70(1):49–54.
- 373 29. A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of  
374 Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial  
375 Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess  
376 Safety and Effect Duration [Internet]. *ACR Meeting Abstracts*. [cited 2024 Mar 1]. Available from:  
377 [https://acrabstracts.org/abstract/a-2-week-single-blind-randomized-3-arm-proof-of-concept-](https://acrabstracts.org/abstract/a-2-week-single-blind-randomized-3-arm-proof-of-concept-study-of-the-effects-of-secukinumab-anti-il17-mab-canakinumab-anti-il-1-b-mab-or-corticosteroids-on-initial-disease-activity-scores-in-p/)  
378 [study-of-the-effects-of-secukinumab-anti-il17-mab-canakinumab-anti-il-1-b-mab-or-](https://acrabstracts.org/abstract/a-2-week-single-blind-randomized-3-arm-proof-of-concept-study-of-the-effects-of-secukinumab-anti-il17-mab-canakinumab-anti-il-1-b-mab-or-corticosteroids-on-initial-disease-activity-scores-in-p/)  
379 [corticosteroids-on-initial-disease-activity-scores-in-p/](https://acrabstracts.org/abstract/a-2-week-single-blind-randomized-3-arm-proof-of-concept-study-of-the-effects-of-secukinumab-anti-il17-mab-canakinumab-anti-il-1-b-mab-or-corticosteroids-on-initial-disease-activity-scores-in-p/)
- 380 30. Teufel LU, Netea MG, van de Veerdonk FL, Dinarello CA, Joosten LAB, Arts RJW. Opposing Effects  
381 of Interleukin-36γ and Interleukin-38 on Trained Immunity. *Int J Mol Sci.* 2023 Jan 24;24(3):2311.
- 382 31. Han Y, Huard A, Mora J, da Silva P, Brüne B, Weigert A. IL-36 family cytokines in protective versus  
383 destructive inflammation. *Cell Signal.* 2020 Nov;75:109773.
- 384 32. Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, et al. Efficacy and safety of  
385 subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2):  
386 an international, multicentre, randomised, placebo-controlled trial. *The Lancet.* 2023 Oct  
387 28;402(10412):1541–51.
- 388 33. Sack GH. Serum amyloid A – a review. *Mol Med.* 2018 Aug 30;24:46.
- 389 34. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. *Eur J*  
390 *Biochem.* 1999 Oct;265(2):501–23.
- 391 35. Shridas P, De Beer MC, Webb NR. High-density lipoprotein inhibits serum amyloid A–mediated  
392 reactive oxygen species generation and NLRP3 inflammasome activation. *J Biol Chem.* 2018 Aug  
393 24;293(34):13257–69.
- 394 36. He M, Liu Y, Chen S, Deng H, Feng C, Qiao S, et al. Serum amyloid A promotes glycolysis of  
395 neutrophils during PD-1 blockade resistance in hepatocellular carcinoma. *Nat Commun.* 2024  
396 Feb 26;15:1754.
- 397 37. O’Neill L, Rooney P, Molloy D, Connolly M, McCormick J, McCarthy G, et al. Regulation of  
398 Inflammation and Angiogenesis in Giant Cell Arteritis by Acute-Phase Serum Amyloid A. *Arthritis*  
399 *Rheumatol.* 2015 Sep;67(9):2447–56.
- 400 38. Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH, et al. Serum Amyloid A Proteins Induce  
401 Pathogenic TH17 Cells and Promote Inflammatory Disease. *Cell.* 2020 Jan 9;180(1):79-91. e16.
- 402 39. Liu D, Chen Y, Wang Y, Lei M, Chen L, Liang R, et al. Combination of Serum Amyloid A and C-  
403 Reactive Protein Exhibit Synergistic Effect in Angiogenesis by Inducing Inflammation and Vascular  
404 Network. *Front Oncol.* 2020 Dec 8;10:576207.
- 405 40. Kerami Z, Duijvis NW, Vogels EW, van Dooren FH, Moerland PD, Te Velde AA. Effect of interleukin-  
406 17 on gene expression profile of fibroblasts from Crohn’s disease patients. *J Crohns Colitis.* 2014  
407 Oct;8(10):1208–16.


- 408 41. Kendal AR, Layton T, Al-Mossawi H, Appleton L, Dakin S, Brown R, et al. Multi-omic single cell  
409 analysis resolves novel stromal cell populations in healthy and diseased human tendon. *Sci Rep.*  
410 2020 Sep 3;10(1):13939.
- 411 42. Koch DW, Berglund AK, Messenger KM, Gilbertie JM, Ellis IM, Schnabel LV. Interleukin-1 $\beta$  in  
412 tendon injury enhances reparative gene and protein expression in mesenchymal stem cells.  
413 *Front Vet Sci.* 2022 Aug 11;9:963759.
- 414 43. Kawata K, Koga H, Tsuji K, Miyatake K, Nakagawa Y, Yokota T, et al. Extracellular vesicles derived  
415 from mesenchymal stromal cells mediate endogenous cell growth and migration via the CXCL5  
416 and CXCL6/CXCR2 axes and repair menisci. *Stem Cell Research & Therapy.* 2021 Jul 22;12(1):414.
- 417 44. Sherwood J, Bertrand J, Nalesso G, Poulet B, Pitsillides A, Brandolini L, et al. A homeostatic  
418 function of CXCR2 signalling in articular cartilage. *Ann Rheum Dis.* 2015 Dec;74(12):2207–15.
- 419 45. Caxaria S, Kouvatso N, Eldridge SE, Alvarez-Fallas M, Thorup A, Cici D, et al. Disease modification  
420 and symptom relief in osteoarthritis using a mutated GCP-2/CXCL6 chemokine. *EMBO Mol Med.*  
421 2022 Dec 12;15(1):e16218.
- 422 46. Ghesmati Z, Rashid M, Fayezi S, Gieseler F, Alizadeh E, Darabi M. An update on the secretory  
423 functions of brown, white, and beige adipose tissue: Towards therapeutic applications. *Rev*  
424 *Endocr Metab Disord.* 2024 Apr 1;25(2):279–308.
- 425 47. Saint-André V, Charbit B, Biton A, Rouilly V, Possémé C, Bertrand A, et al. Smoking changes  
426 adaptive immunity with persistent effects. *Nature.* 2024 Feb;626(8000):827–35.
- 427 48. Tomlinson DJ, Erskine RM, Morse CI, Pappachan JM, Sanderson-Gillard E, Onambélé-Pearson GL.  
428 The combined effects of obesity and ageing on skeletal muscle function and tendon properties in  
429 vivo in men. *Endocrine.* 2021;72(2):411–22.
- 430 49. Lui PPY, Yung PSH. Inflammatory mechanisms linking obesity and tendinopathy. *J Orthop*  
431 *Translat.* 2021 Dec 9;31:80–90.
- 432

**Table 1.** Genetic loci associated with PMR at the genome-wide significance level.

rsID for lead variant	Variant position (Ch37/hg19)	Nearest gene	EA	NEA	EAF	Beta	SE	<i>P value</i>	OR	Previously known
rs11694915	2:102710068	<i>IL1R1</i>	A	T	0.3865	-0.0978	0.0172	1.40E-08	0.91	No
rs748741	9:127089775	<i>NEK6</i>	A	G	0.6168	-0.0959	0.0172	2.31E-08	0.91	No
rs615540	11:64123838	<i>CCDC88B</i>	A	G	0.5489	0.1056	0.0169	3.70E-10	1.11	No
rs2760985	6:32566398	<i>HLA-DRB1</i>	A	G	0.2181	0.5307	0.0209	7.78E-142	1.70	Yes
rs7731626	5:55444683	<i>ANKRD55</i>	A	G	0.3123	-0.1618	0.0181	4.59E-19	0.85	Yes

EA, effect allele; EAF, effect allele frequency; NEA, non-effect allele; SE, standard error.


**Figure 1.** Results of genome-wide association study in PMR and summary of 5 identified genomic risk loci.



SNPs, single nucleotide polymorphisms.




**Figure 2.** Associations between genetically proxied modifiable factors and the risk of PMR in Mendelian randomization analysis.





Legend: FDR, false discovery rate correction for eight risk factors. Bars show 95% confidence interval. OR, odds ratio, estimate per standard deviation increase in all risk factors, except for coffee consumption (per 50% change in intake) and physical activity (being active verses inactive).

**Figure 3.** Associations between genetically predicted levels of inflammatory markers and the risk of PMR in Mendelian randomization analysis.




A. volcano plot of MR associations between 65 inflammatory markers and PMR. B. forest plot of 12 associations with P value < 0.05. Estimates were scaled to one standard deviation increase in genetically predicted markers.





A



B

